Hydropothecary launches Elixir CBD Peppermint – Canada’s first CBD medical cannabis oil mist
GATINEAU, QC–(Marketwired – February 01, 2018) – The Hydropothecary Corporation (“Hydropothecary” or the “Company”) (TSX VENTURE: THCX) today released Elixir CBD Peppermint, Canada’s first CBD medical cannabis oil mist.
“Hydropothecary is committed to developing innovative medical cannabis products in response to our clients’ daily living needs. Our award-winning Elixir THC Peppermint product was created for people seeking an easy-to-use, discreet cannabis product suited to their busy lifestyles. With Elixir CBD Peppermint, we are responding to clients also looking for convenient and easy to use ways to consume CBD,” said Mr. Guy DeGrace, Hydropothercary’s Community Engagement Manager for Quebec and Eastern Canada.
With less than 4 mg/ml of THC and between 50 to 60 mg/ml of CBD, Elixir CBD Peppermint delivers the therapeutic benefits of CBD to patients while minimizing the psychoactive effects of THC.
“There’s been a lot of interest in CBD from medical cannabis clinics and patients. Elixir CBD Peppermint features the highest concentration of CBD per ml currently available to medical cannabis patients,” noted Hart Steinfeld, Hydropothecary’s Community Engagement Manager for Western Canada.
Like the award-winning Elixir THC Peppermint, the Company’s convenient new Elixir CBD Peppermint product contains cannabis oil in a refreshing naturally-derived peppermint oil. Elixir CBD Peppermint comes in a child-resistant bottle and can be used under the tongue or mixed with food or liquids.
Elixir CBD Peppermint ($89/15ml bottle) and Elixir THC Peppermint ($69/15ml bottle) are available at the Hydropothecary’s online store or by telephone from the 24/7 bilingual hotline at 1-844-406-1852.
For more information on Elixir CBD Peppermint or Elixir THC Peppermint, please visit www.thehydropothecary.com/products#
About Hydropothecary Corporation
The Hydropothecary Corporation is an authorized licensed producer and distributor of medical cannabis licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (Canada). Hydropothecary creates award-winning innovative, easy to use and easy to understand products. Hydropothecary is rapidly increasing its production capacity in the lead-up to recreational adult-use cannabis. Expansion plans will result in a total of 1.3 million sq. ft. of production space, producing 108,000 kg of dried cannabis per year, making Hydropothecary one of the largest producers in the country. With industry-leading cash cost per gram of $0.89, Hydropothecary is the lowest cost producer in the country. The first licensed producer in Quebec, Hydropothecary is headquartered in the province.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Media Contact Information
Investor Relations Contact Information
Manager of Financial Reporting and Investor Relations